US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.71 against a street estimate of 1.53 — a beat of 11.8%.
Analysts rate Collegium Pharmaceutical Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $49.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.71% |
| Jupiter Topco LLC | 6.60% |
| Amvescap Plc. | 5.78% |
| Fuller & Thaler Asset Management Inc | 5.02% |
| Principal Financial Group Inc | 5.01% |
| State Street Corp | 4.70% |
| Massachusetts Financial Services Company | 4.32% |
| Vanguard Capital Management, LLC | 4.24% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 product revenue was $216.339 million, up from $209.361 million in the third quarter of 2025. • Nine-month 2026 | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 product revenues were $216.3 million, up 3% year-over-year from $209.4 million. • GAAP net income was $21.8 million, vers | 2026-11-05 |
| Current report · Q4 2026 HEADLINE NUMBERS • Collegium Pharmaceutical paid Grunenthal GmbH $17,000,000 on October 15, 2026 to settle all disputes, including patent litigation | 2026-10-19 |
| Company announcement · Q3 2026 COLLEGIUM PHARMACEUTICAL, INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company announced execution of accelerated share repurchase (ASR) agreement on | 2026-08-13 |
| Quarterly report · Q2 2026 COLLEGIUM PHARMACEUTICAL, INC. — Q2 2026 SUMMARY HEADLINE NUMBERS • Product revenues (6 months ended June 30, 2026): $393,398 thousand, up from $365 | 2026-08-06 |
| Results announced · Q3 2026 COLLEGIUM PHARMACEUTICAL Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 Total Product Revenues: $199.9 million, up 6% year-over-yea | 2026-08-06 |
| Shareholder vote results · Q2 2026 COLLEGIUM PHARMACEUTICAL, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 14, 2026 • 32,406,969 total shares entitled to vote as | 2026-05-15 |
| Acquisition completed · Q2 2026 COLLEGIUM PHARMACEUTICAL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed acquisition of AZSTARYS® on May 12, 2026 for approximately $6 | 2026-05-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Collegium Pharmaceutical Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.